Msd Merck Co Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MSD MERCK CO, and what generic alternatives to MSD MERCK CO drugs are available?
MSD MERCK CO has five approved drugs.
There are five US patents protecting MSD MERCK CO drugs.
There are one hundred and eighty-nine patent family members on MSD MERCK CO drugs in fifty-one countries and eighty-eight supplementary protection certificates in sixteen countries.
Drugs and US Patents for Msd Merck Co
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Msd Merck Co | EMEND | aprepitant | FOR SUSPENSION;ORAL | 207865-001 | Dec 17, 2015 | RX | Yes | Yes | 8,258,132 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Msd Merck Co | DELSTRIGO | doravirine; lamivudine; tenofovir disoproxil fumarate | TABLET;ORAL | 210807-001 | Aug 30, 2018 | RX | Yes | Yes | 10,603,282 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Msd Merck Co | RECARBRIO | cilastatin sodium; imipenem; relebactam | POWDER;INTRAVENOUS | 212819-001 | Jul 16, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Msd Merck Co | RECARBRIO | cilastatin sodium; imipenem; relebactam | POWDER;INTRAVENOUS | 212819-001 | Jul 16, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Msd Merck Co | NOXAFIL POWDERMIX KIT | posaconazole | FOR SUSPENSION, DELAYED RELEASE;ORAL | 214770-001 | May 31, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Msd Merck Co
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Msd Merck Co | EMEND | aprepitant | FOR SUSPENSION;ORAL | 207865-001 | Dec 17, 2015 | 6,096,742 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for MSD MERCK CO drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 115 mg/vial | ➤ Subscribe | 2012-01-25 |
➤ Subscribe | for Oral Suspension | 125 mg/Kit | ➤ Subscribe | 2016-11-23 |
➤ Subscribe | Capsule | 40 mg, 80 mg and 125 mg | ➤ Subscribe | 2008-11-03 |
➤ Subscribe | Injection | 150 mg/vial | ➤ Subscribe | 2012-01-25 |
International Patents for Msd Merck Co Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Africa | 200404012 | ⤷ Sign Up |
Montenegro | 02089 | ⤷ Sign Up |
Spain | 2536295 | ⤷ Sign Up |
Montenegro | 02181 | ⤷ Sign Up |
Israel | 206395 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Msd Merck Co Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2666774 | 132020000000070 | Italy | ⤷ Sign Up | PRODUCT NAME: RELEBACTAM, OPZIONALMENTE IN FORMA DEL MONOIDRATO, E IMIPENEM(RECARBRIO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1420, 20200217 |
0734381 | SPC/GB04/011 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113 |
2924034 | C201930027 | Spain | ⤷ Sign Up | PRODUCT NAME: DORAVIRINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA EN COMBINACION CON LAMIVUDINA Y TENOFOVIR DISOPROXILO FUMARATO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1333; DATE OF AUTHORISATION: 20181122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1333; DATE OF FIRST AUTHORISATION IN EEA: 20181122 |
2666774 | 31/2020 | Austria | ⤷ Sign Up | PRODUCT NAME: RELEBACTAM, GEGEBENENFALLS IN DER FORM DES MONOHYDRATS, IMIPENEM UND CILASTATIN, GEGEBENENFALLS IN DER FORM DES NATRIUMSALZES.; REGISTRATION NO/DATE: EU/1/19/1420 (MITTEILUNG) 20200217 |
2552902 | 2019019 | Norway | ⤷ Sign Up | PRODUCT NAME: DORAVIRIN ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV; REG. NO/DATE: EU/1/18/1332/001-2 20181213 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.